ROMJF
Price
$0.46
Change
-$0.01 (-2.13%)
Updated
Sep 4 closing price
Capitalization
28.73M
SGIOF
Price
$19.00
Change
+$1.04 (+5.79%)
Updated
Sep 3 closing price
Capitalization
15.32B
Interact to see
Advertisement

ROMJF vs SGIOF

Header iconROMJF vs SGIOF Comparison
Open Charts ROMJF vs SGIOFBanner chart's image
Rubicon Organics
Price$0.46
Change-$0.01 (-2.13%)
Volume$4.77K
Capitalization28.73M
Shionogi & Co
Price$19.00
Change+$1.04 (+5.79%)
Volume$101
Capitalization15.32B
ROMJF vs SGIOF Comparison Chart in %
Loading...
ROMJF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGIOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ROMJF vs. SGIOF commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ROMJF is a Hold and SGIOF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ROMJF: $0.46 vs. SGIOF: $19.00)
Brand notoriety: ROMJF and SGIOF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ROMJF: 2% vs. SGIOF: 15%
Market capitalization -- ROMJF: $28.73M vs. SGIOF: $15.32B
ROMJF [@Pharmaceuticals: Generic] is valued at $28.73M. SGIOF’s [@Pharmaceuticals: Generic] market capitalization is $15.32B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ROMJF’s FA Score shows that 0 FA rating(s) are green whileSGIOF’s FA Score has 2 green FA rating(s).

  • ROMJF’s FA Score: 0 green, 5 red.
  • SGIOF’s FA Score: 2 green, 3 red.
According to our system of comparison, SGIOF is a better buy in the long-term than ROMJF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ROMJF’s TA Score shows that 5 TA indicator(s) are bullish while SGIOF’s TA Score has 4 bullish TA indicator(s).

  • ROMJF’s TA Score: 5 bullish, 4 bearish.
  • SGIOF’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, ROMJF is a better buy in the short-term than SGIOF.

Price Growth

ROMJF (@Pharmaceuticals: Generic) experienced а -5.04% price change this week, while SGIOF (@Pharmaceuticals: Generic) price change was +5.79% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.80%. For the same industry, the average monthly price growth was +10.24%, and the average quarterly price growth was +86.08%.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.80% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SGIOF($15.3B) has a higher market cap than ROMJF($28.7M). ROMJF has higher P/E ratio than SGIOF: ROMJF (60.49) vs SGIOF (14.04). SGIOF YTD gains are higher at: 55.610 vs. ROMJF (40.755). SGIOF has higher annual earnings (EBITDA): 206B vs. ROMJF (3.31M). SGIOF has more cash in the bank: 576B vs. ROMJF (7.78M). ROMJF has less debt than SGIOF: ROMJF (9.7M) vs SGIOF (11.7B). SGIOF has higher revenues than ROMJF: SGIOF (419B) vs ROMJF (52.2M).
ROMJFSGIOFROMJF / SGIOF
Capitalization28.7M15.3B0%
EBITDA3.31M206B0%
Gain YTD40.75555.61073%
P/E Ratio60.4914.04431%
Revenue52.2M419B0%
Total Cash7.78M576B0%
Total Debt9.7M11.7B0%
FUNDAMENTALS RATINGS
ROMJF vs SGIOF: Fundamental Ratings
ROMJF
SGIOF
OUTLOOK RATING
1..100
737
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
922
PRICE GROWTH RATING
1..100
3742
P/E GROWTH RATING
1..100
3738
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SGIOF's Valuation (24) in the null industry is somewhat better than the same rating for ROMJF (71). This means that SGIOF’s stock grew somewhat faster than ROMJF’s over the last 12 months.

SGIOF's Profit vs Risk Rating (100) in the null industry is in the same range as ROMJF (100). This means that SGIOF’s stock grew similarly to ROMJF’s over the last 12 months.

SGIOF's SMR Rating (2) in the null industry is significantly better than the same rating for ROMJF (92). This means that SGIOF’s stock grew significantly faster than ROMJF’s over the last 12 months.

ROMJF's Price Growth Rating (37) in the null industry is in the same range as SGIOF (42). This means that ROMJF’s stock grew similarly to SGIOF’s over the last 12 months.

ROMJF's P/E Growth Rating (37) in the null industry is in the same range as SGIOF (38). This means that ROMJF’s stock grew similarly to SGIOF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ROMJFSGIOF
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
57%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
60%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 2 days ago
48%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
53%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
44%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
51%
Advances
ODDS (%)
Bullish Trend 4 days ago
71%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
43%
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
39%
View a ticker or compare two or three
Interact to see
Advertisement
ROMJF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGIOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NAIL90.187.31
+8.82%
Direxion Daily Hmbldrs&Supls Bull 3X ETF
FTDS55.810.53
+0.95%
First Trust Dividend Strength ETF
IEUS65.840.35
+0.53%
iShares MSCI Europe Small-Cap ETF
ARKK75.020.23
+0.31%
ARK Innovation ETF
YFYA9.880.01
+0.10%
Yields for You Strategy A ETF

ROMJF and

Correlation & Price change

A.I.dvisor tells us that ROMJF and SGIOF have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ROMJF and SGIOF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ROMJF
1D Price
Change %
ROMJF100%
-3.04%
SGIOF - ROMJF
8%
Poorly correlated
N/A
SGIOY - ROMJF
8%
Poorly correlated
N/A
RSCI - ROMJF
5%
Poorly correlated
N/A
TEVJF - ROMJF
4%
Poorly correlated
N/A
PCLOF - ROMJF
3%
Poorly correlated
+21.87%
More

SGIOF and

Correlation & Price change

A.I.dvisor tells us that SGIOF and AGYTF have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SGIOF and AGYTF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SGIOF
1D Price
Change %
SGIOF100%
N/A
AGYTF - SGIOF
25%
Poorly correlated
N/A
HLNCF - SGIOF
21%
Poorly correlated
+1.29%
SFOSF - SGIOF
11%
Poorly correlated
+0.19%
ROMJF - SGIOF
8%
Poorly correlated
-3.04%
TEVJF - SGIOF
8%
Poorly correlated
N/A
More